Literature DB >> 10818259

Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody.

A Fassio1, G Evans, R Grisshammer, J P Bolam, M Mimmack, P C Emson.   

Abstract

The distribution of neurotensin receptor 1 immunoreactivity in the rat brain was studied using an antibody against the amino-terminal of the receptor expressed as a fusion protein with glutathione-S transferase. Affinity purified antibodies detected the fusion protein and the complete neurotensin receptor sequence expressed in Escherichia coli. The immunostaining was abolished by preabsorption with the amino-terminal fusion protein. Immunoreactive neurotensin receptor 1 immunoreactivity was detected on cell bodies and their processes in a number of CNS regions. In agreement with previous binding studies neurotensin receptor 1 immunoreactivity was particularly localised in cell bodies in the basal forebrain, nucleus basalis and substantia nigra. At the electron microscope level immunoreactivity was found both in axonal bouton and dendrites and spines in the basal forebrain indicating that neurotensin may act both pre- and post-synaptically. There were several regions such as the substantia gelatinosa, ventral caudate-putamen and the lateral reticular nucleus where the neurotensin receptor 1 positive cells had not previously been reported, indicating that distribution of this receptor is widespread.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818259     DOI: 10.1016/s0028-3908(00)00060-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  25 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

Review 2.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

3.  Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Authors:  Moonnoh R Lee; David J Hinton; Sencan S Unal; Elliott Richelson; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

Review 4.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

5.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

6.  Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABAA and GABAB receptor-mediated synaptic input.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

7.  MicroRNA-133α regulates neurotensin-associated colonic inflammation in colonic epithelial cells and experimental colitis.

Authors:  Ivy Ka Man Law; Charalabos Pothoulakis
Journal:  RNA Dis       Date:  2015

8.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

9.  Intrathecal neurotensin is hypotensive, sympathoinhibitory and enhances the baroreflex in anaesthetized rat.

Authors:  B Zogovic; P M Pilowsky
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

10.  Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity.

Authors:  Geneviève Roussy; Marc-André Dansereau; Stéphanie Baudisson; Faouzi Ezzoubaa; Karine Belleville; Nicolas Beaudet; Jean Martinez; Elliott Richelson; Philippe Sarret
Journal:  Mol Pain       Date:  2009-07-06       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.